首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   444篇
  免费   31篇
  国内免费   13篇
耳鼻咽喉   1篇
儿科学   17篇
妇产科学   10篇
基础医学   33篇
口腔科学   17篇
临床医学   54篇
内科学   97篇
皮肤病学   17篇
神经病学   2篇
特种医学   127篇
外科学   29篇
综合类   11篇
预防医学   17篇
眼科学   3篇
药学   13篇
肿瘤学   40篇
  2023年   1篇
  2021年   4篇
  2020年   2篇
  2019年   3篇
  2018年   9篇
  2017年   4篇
  2016年   5篇
  2015年   12篇
  2014年   5篇
  2013年   20篇
  2012年   6篇
  2011年   7篇
  2010年   14篇
  2009年   25篇
  2008年   6篇
  2007年   24篇
  2006年   12篇
  2005年   8篇
  2004年   2篇
  2003年   3篇
  2002年   5篇
  2001年   9篇
  2000年   2篇
  1999年   8篇
  1998年   51篇
  1997年   45篇
  1996年   22篇
  1995年   23篇
  1994年   12篇
  1993年   12篇
  1992年   2篇
  1991年   4篇
  1990年   8篇
  1989年   10篇
  1988年   13篇
  1987年   13篇
  1986年   11篇
  1985年   10篇
  1984年   9篇
  1983年   8篇
  1982年   6篇
  1981年   6篇
  1980年   9篇
  1979年   3篇
  1977年   3篇
  1976年   2篇
  1975年   6篇
  1957年   2篇
  1956年   2篇
排序方式: 共有488条查询结果,搜索用时 15 毫秒
51.
目的:观察妇科开腹手术患者术前给予依他昔布120mg对术后自控镇痛(PCA)吗啡用量的影响及其副作用。方法:随机选取全麻下接受妇科开腹全子宫(双附件)切除患者40例,术前分别给予安慰剂或依他昔布120mg口服。在手术后观察24h患者PCA吗啡用量,同时记录患者的疼痛评分和满意度评分,并观察不良反应。结果:术后PCA吗啡24h消耗量在依他昔布组为9.4±7.6mg,显著低于安慰剂组15.7±8.9mg。两组患者24h内对PCA的按压次数依他昔布组也低于安慰剂组(P<0.05)。其中术后3、6、8和12hPCA吗啡消耗量在两组间无显著差异。两组患者术后24h疼痛评分和对镇痛治疗的满意度也无差异。两组患者不良反应的发生率亦无差别。结论:在妇科开腹手术患者术前应用依他昔布120mg可使患者术后PCA吗啡消耗量降低,且在术后12h后下降明显。未发现与依他昔布应用相关的副作用。  相似文献   
52.

Background  

Potassium disorders can cause major complications and must be avoided in critically ill patients. Regulation of potassium in the intensive care unit (ICU) requires potassium administration with frequent blood potassium measurements and subsequent adjustments of the amount of potassium administrated. The use of a potassium replacement protocol can improve potassium regulation. For safety and efficiency, computerized protocols appear to be superior over paper protocols. The aim of this study was to evaluate if a computerized potassium regulation protocol in the ICU improved potassium regulation.  相似文献   
53.
In 22 hemodialysis patients, during a dialysis session, the solute removal index (SRI) for urea obtained from the use of a partial spent dialysate collection method was compared with that derived from the use of a total spent dialysate collection technique. The partial spent dialysate collection method was used to harvest a small representative sample of the total spent dialysate. The volumes of spent dialysate collected by the partial and the total spent dialysate collection methods were 1.7 +/- 0.4 L and 129.6 +/- 15.3 L, respectively. The total amount of urea nitrogen removed by dialysis as estimated by the partial spent dialysate collection method was similar to that determined by the total spent dialysate collection approach. As a result, the SRI value for urea obtained by the partial spent dialysate collection method (namely, 63% +/- 8%) correlated very well (r = 0.95, P < 0.001) with that derived by the total spent dialysate collection technique (namely, 62% +/- 8%). Our data suggest that it is feasible to use a simple partial spent dialysate collection method to obtain SRI results in patients treated with hemodialysis.  相似文献   
54.
Tagged MR imaging in a deforming phantom: photographic validation   总被引:1,自引:0,他引:1  
Moore  CC; Reeder  SB; McVeigh  ER 《Radiology》1994,190(3):765
  相似文献   
55.
56.
The transforming growth factor-beta type II receptor (RII) is commonly mutated in colon and gastric cancers with microsatellite instability (MI). We utilized our series of lung cancers with MI and rare alleles of the H-ras1 gene to determine the association between MI and RII mutations and searched the entire RII coding region in 33 lung cancers with MI by polymerase chain reaction-single-strand conformation polymorphism analysis. We found no mutations, and these data support other recent evidence that RII mutations rarely occur except in colon and gastric tumors with MI.   相似文献   
57.
58.

Background  

Pneumocystis jiroveci pneumonia (PCP) is an important opportunistic infection among immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV). The clinical presentation of PCP in immunosuppressed patients have been well-reported in the literature. However, the clinical importance of PCP manifesting in the setting of an immunorestitution disease (IRD), defined as an acute symptomatic or paradoxical deterioration of a (presumably) preexisting infection, which is temporally related to the recovery of the immune system and is due to immunopathological damage associated with the reversal of immunosuppressive processes, has received relatively little attention until recently.  相似文献   
59.
Greenberg  CS; Miraglia  CC 《Blood》1985,66(2):466-469
The effect of fibrin polymers on thrombin-catalyzed factor XIIIa formation was studied in afibrinogenemic plasma. Fibrin polymers derived from des A fibrinogen and des A,B fibrinogen increased sixfold the rate of thrombin-catalyzed factor XIIIa formation in the presence of EDTA. Calcium chloride accelerated factor XIIIa formation 14-fold in the presence of des A,B fibrinogen without increasing the rate of thrombin formation. Fibrinopeptides A and B had no effect on factor XIIIa formation in afibrinogenemic plasma. Des A,B fibrinogen reduced by 20- to 40-fold the thrombin concentration required to activate factor XIII. Glycyl-L-prolyl-L-arginyl-L-proline (gly-pro-arg-pro), a fibrin polymerization inhibitor, inhibited des A and des A,B fibrinogen from enhancing thrombin-catalyzed factor XIIIa formation. Gly-pro-arg- pro did not modify factor XIIIa formation in afibrinogenemic plasma and did not inhibit thrombin cleavage of the chromogenic substrate S-2238. These results demonstrate that fibrin polymers accelerate thrombin- catalyzed plasma factor XIIIa formation.  相似文献   
60.
AP-1和肿瘤的关系研究进展   总被引:4,自引:0,他引:4  
转录因子AP-1(activatorprotein1),主要由Jun、Fos、ATF及JDP亚家族组成,亚家族单体以同源或异源二聚体的形式结合DNA靶序列,参与靶基因调节.对基因修饰小鼠和细胞的研究表明,AP-1参与细胞的正常生长和癌性转化过程,其在细胞中的作用取决于细胞类型、AP-1的组成和各组分的相对比例,也与刺激的种类密切相关.AP-1的活性受多种核因子调节,同时单体间也存在相互促进或拮抗作用.AP-1对各种刺激如应激、辐射或生长信号等作出生理或病理应答,参与细胞的增殖、分化和转化等过程,在肿瘤的形成、转移和侵袭中发挥重要作用,已经有学者研究通过抑制AP-1活性来发展抗肿瘤药物.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号